Table 1.
Patient histories
| Patient No | Age/sex | Disease | Duration of IBD (yr) | Localization | CDAI before/after 6 cycles | UC-DAI before/after 6 cycles | Maintenance therapy for remission |
| 1 | 46/female | CD | 26 | colon-rectum | 168/79 | methotrexate | |
| 2 | 65/female | CD | 18 | ileum-colon-rectum | 231/86 | methotrexate | |
| 3 | 49/female | CD | 22 | ileum-colon | 198/91 | methotrexate | |
| 4 | 36/female | CD | 5 | ileum-colon | 242/98 | methotrexate | |
| 5 | 59/male | UC | 5 | rectum | 14/6 | azathioprine | |
| 6 | 44/male | UC | 5 | rectum | 15/8 | azathioprine | |
| 7 | 29/male | UC | 4 | recto-sigmoid | 13/6 | azathioprine | |
| 8 | 29/male | UC | 8 | recto-sigmoid | 14/7 | azathioprine |
UC-DAI: Modified Truelove and Witts activity index for UC; CDAI: CD activity index; Methotrexate: 15 mg/wk; Azathioprine: 2.5 mg/kg body weight per day.